Rapport Therapeutics, Inc. Common Stock (RAPP) vs Ultragenyx Pharmaceutical Inc. (RARE)

A side-by-side comparison of Rapport Therapeutics, Inc. Common Stock and Ultragenyx Pharmaceutical Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Rapport Therapeutics, Inc. Common Stock logo
RAPP
Rapport Therapeutics, Inc. Common Stock
$1.46B
$30.44HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
Ultragenyx Pharmaceutical Inc. logo
RARE
Ultragenyx Pharmaceutical Inc.
$1.43B
$14.50HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT

Total return — RAPP vs RARE

growth of $100 · dividends reinvested · last 2y
RAPP +54.8% (+24.4%/yr)RARE -65.3% (-41.1%/yr)RAPP compounded faster over this window
50100150200250Start $10020252026$155$35
RAPP RARE

RAPP vs RARE: by the numbers

  • •RAPP is the larger company ($1.46B vs $1.43B market cap).
  • •Both run net losses; RARE's is the smaller (-81.79% vs -685.80% net margin).

Metrics side by side

Valuation

MetricRAPPRARE
P/S ratio72.801.99
P/B ratio3.44N/A

Profitability

MetricRAPPRARE
Gross margin0.00%83.12%
Operating margin0.00%-73.77%
Net margin-685.80%-81.79%
ROE-32.43%N/A
ROIC-35.66%-53.48%

Growth (annualized)

MetricRAPPRARE
Revenue CAGR (5Y)N/A14.81%
Total return CAGR (5Y)N/A-30.14%

Go deeper

Full RAPP analysisFull RARE analysisInteractive comparison tool

Dig into the metrics

Rapport Therapeutics, Inc. Common Stock ROEUltragenyx Pharmaceutical ROERapport Therapeutics, Inc. Common Stock operating marginUltragenyx Pharmaceutical operating marginRapport Therapeutics, Inc. Common Stock revenue growthUltragenyx Pharmaceutical revenue growthRapport Therapeutics, Inc. Common Stock free cash flowUltragenyx Pharmaceutical free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.